| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Welcome to the official corporate Facebook page of Adaptec by PMC. We update our web site (adaptec.com) on an ongoing basis with new technical/product information, upcoming events, videos, news and media coverage, but youll read about them here first....
An Anderson Community is a Better Place to Live!
Clubhouse is a new type of social product based on voice. It allows people everywhere to talk, tell stories, develop ideas, deepen friendships, and meet interesting new people around the world. Our early users love the product and we have been featured in publications like The New York Times, Forbes, The Telegraph, TechCrunch, The Information, CNBC, and WIRED — as well as a huge range of thoughtful blog posts. Today, we are a small and productive team with a strong background in consumer products. We are well funded, with recent backing from top-tier VCs and many of the best angel investors in Silicon Valley.
Each year, Breakthrough hosts an event called The Mercury Group. This annual gathering of shipper clients invites attendees to...